Trial Profile
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs Fezagepras (Primary)
- Indications Metabolic syndrome; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Liminal BioSciences
- 14 Jun 2019 According to a ProMetic Life Sciences media release, data demonstrating that PBI-4050 reduced biomarkers associated with kidney injury from this study along with results from cellular and animal models of acute and chronic kidney injuries will be presented in an oral presentation at the 56th Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) (on 14th Jun 2019).
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association